Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

As part of a strategy to strengthen its immunology segment through acquisitions, Sanofi has agreed to buy US-based Blueprint ...

Sanofi will purchase Blueprint Medicines for $129 per share in cash, with additional non-tradable contingent value rights (CVRs) of up to $6 per share tied to the development and regulatory ...

Citizens JMP analyst Reni Benjamin downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Market Perform from Outperform ...

On Wednesday, Citi analysts upgraded Blueprint Medicines (NASDAQ:BPMC) stock to Neutral from a previous rating, following the announcement of its acquisition by Sanofi (NASDAQ:SNY). The ...

Stephens & Co. analyst Sudan Loganathan downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Equal Weight from ...

On Wednesday, Citi analysts upgraded Blueprint Medicines (NASDAQ:BPMC) stock to Neutral from a previous rating, following the announcement of its acquisition by Sanofi (EPA:SASY) (NASDAQ:SNY). The ...

SNY, BMY, REGN and others ramp up 2025 dealmaking as pharma/biotech giants chase innovation across key growth areas.

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...